Next 10 |
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treat...
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors Preclinical synergy data in prostate cancer models reinforces th...
2024-03-29 05:29:56 ET Summary ORIC Pharmaceuticals' stock has seen significant gains since releasing promising data from its ORIC-114 program, which induced multiple partial responses in NSCLC patients. The company focuses on developing therapies to counter resistance mechanisms ...
2024-03-13 08:19:27 ET Summary ORIC Pharmaceuticals has reported positive preliminary results for three programs in its pipeline: ORIC-944, ORIC-114, and ORIC-533. ORIC-944, for the treatment of metastatic prostate cancer, is expected to initiate a combination study in the first h...
2024-03-12 14:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for ORIC on March 12, 2024 12:55PM ET. The previous analyst recommendation was Outperform. ORIC was trading at $14.62 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-03-12 14:00:02 ET David Nierengarten from Wedbush issued a price target of $20.00 for ORIC on 2024-03-12 12:55:00. The adjusted price target was set to $20.00. At the time of the announcement, ORIC was trading at $14.63. The overall price target consensus is at $7.0...
2024-03-11 17:01:32 ET More on ORIC Pharmaceuticals Cantor starts ORIC at overweight, cites potential of ORIC-114 ORIC Pharmaceuticals stock rises after it announces $125M private placement Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...
Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of combination study of ORIC-944 with AR inhibitor(s) in metastatic prostate...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will present a company ove...
News, Short Squeeze, Breakout and More Instantly...
Oric Pharmaceuticals Inc. Company Name:
ORIC Stock Symbol:
NASDAQ Market:
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treat...
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors Preclinical synergy data in prostate cancer models reinforces th...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...